Meeting
2013 ASCO Annual Meeting
Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial.
Authors
Evanthia Galanis
Mayo Clinic, Rochester, MN
Evanthia Galanis , Jann Nagina Sarkaria , S. Keith Anderson , Wenting Wu , Kurt A. Jaeckle , Caterina Giannini , Jan C. Buckner , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00731731
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2046)
DOI
10.1200/jco.2013.31.15_suppl.2046
Abstract #
2046
Poster Bd #
2B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg
Poster
2013 ASCO Annual Meeting
RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
First Author: Prakash Chinnaiyan